Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 13/20 | 0.49 |
| ▸ | CTSD | P07339 | 4/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.48 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.47 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30123079 | 0.96 | DPP4 (0.51) | BACE1CTSDDPP4DPP8DPP9 | |
| SCHEMBL29531593 | 0.96 | DPP4 (0.51) | BACE1CTSDDPP4DPP8DPP9 | |
| SCHEMBL30728886 | 0.96 | DPP4 (0.51) | BACE1CTSDDPP4DPP8DPP9 | |
| SCHEMBL31181278 | 0.95 | BACE1 (0.53) | BACE1CTSDDPP4DPP8DPP9 | |
| SCHEMBL31234146 | 0.91 | BACE1 (0.51) | BACE1CTSDDPP4DPP8DPP9 | |
| SCHEMBL31064920 | 0.89 | BACE1 (0.48) | BACE1CTSDDPP4DPP8DPP9 | |
| SCHEMBL30220502 | 0.88 | BACE1 (0.49) | BACE1CTSDBACE2ENPEP | |
| SCHEMBL6386178 | 0.88 | DPP4 (0.54) | BACE1CTSDDPP4DPP8DPP9 | |
| SCHEMBL30997439 | 0.88 | DPP4 (0.54) | BACE1CTSDDPP4DPP8DPP9 | |
| SCHEMBL30053992 | 0.88 | PDCD1LG2 (0.48) | BACE1CTSDBACE2ENPEPMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119686702-A | Gas storage injection and production collaborative operation method | 中国石油天然气股份有限公司 | 2025-03-25 | — | — | CN | claimed |
| CN-119321294-A | Salt cavern gas storage brine discharge and water mixing salt accumulation prevention system and operation method thereof | 中国石油化工股份有限公司 | 2025-01-17 | — | — | CN | claimed |
| US-20240301003-A1 | PLASMIN-RESISTANT PEPTIDES FOR IMPROVED THERAPEUTIC INDEX | NONO INC. (CA) | 2024-09-12 | — | — | US | claimed |
| CN-118143897-A | Method suitable for online maintenance of emergency cut-off valve of high-sulfur-content gas field | 中国石油化工股份有限公司 | 2024-06-07 | — | — | CN | claimed |
| US-11878044-B2 | Combination therapy for ischemia | NONO INC. (CA) | 2024-01-23 | — | — | US | claimed |
| EP-4274596-A1 | PLASMIN-RESISTANT PEPTIDES FOR IMPROVED THERAPEUTIC INDEX | NoNO Inc. (CA) | 2023-11-15 | — | — | EP | claimed |
| CN-116897051-A | Plasmin peptides for increasing therapeutic index | 诺诺公司 | 2023-10-17 | — | — | CN | claimed |
| WO-2022150655-A1 | PLASMIN-RESISTANT PEPTIDES FOR IMPROVED THERAPEUTIC INDEX | NONO INC. (CA) | 2022-07-14 | — | — | WO | claimed |
| CN-215635067-U | ESDV valve | 中国石油化工股份有限公司 | 2022-01-25 | — | — | CN | claimed |
| CN-118143897-B | Method suitable for online maintenance of emergency cut-off valve of high-sulfur-content gas field | 中国石油化工股份有限公司 | 2026-05-05 | — | — | CN | disclosed |
| US-20260118363-A1 | Application of GLUN2A and NMDA Receptor Containing GLUN2A as Targets in Screening Drugs for Treating Depression | SYNPHATEC SHANGHAI BIOPHARMACEUTICAL TECH CO LTD (CN) | 2026-04-30 | — | — | US | disclosed |
| EP-4706670-A1 | PSD-95 DOMAIN INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) | 2026-03-11 | — | — | EP | disclosed |
| US-12471388-B2 | Semiconductor device | SOCIONEXT INC. (JP) | 2025-11-11 | — | — | US | disclosed |
| US-12459814-B2 | Steam reforming | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2025-11-04 | — | — | US | disclosed |
| US-20160176924-A1 | MODIFIED PEPTIDES AS POTENT INHIBITORS OF THE PSD-95/NMDA RECEPTOR INTERACTION | UNIVERSITY OF COPENHAGEN (DK) | 2016-06-23 | — | — | US | disclosed |
| US-20160176924-A1 | MODIFIED PEPTIDES AS POTENT INHIBITORS OF THE PSD-95/NMDA RECEPTOR INTERACTION | UNIVERSITY OF COPENHAGEN (DK) | 2016-06-23 | — | — | US | disclosed |
| US-9241967-B2 | Modified peptides as potent inhibitors of the PSD-95/NMDA receptor interaction | UNIVERSITY OF COPENHAGEN (DK) | 2016-01-26 | — | — | US | disclosed |
| US-9241967-B2 | Modified peptides as potent inhibitors of the PSD-95/NMDA receptor interaction | UNIVERSITY OF COPENHAGEN (DK) | 2016-01-26 | — | — | US | disclosed |
| US-20110178022-A1 | MODIFIED PEPTIDES AS POTENT INHIBITORS OF THE PSD-95/NMDA RECEPTOR INTERACTION | UNIVERSITY OF COPENHAGEN (DK) | 2011-07-21 | — | — | US | disclosed |
| US-20110178022-A1 | MODIFIED PEPTIDES AS POTENT INHIBITORS OF THE PSD-95/NMDA RECEPTOR INTERACTION | UNIVERSITY OF COPENHAGEN (DK) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260118363-A1 | Application of GLUN2A and NMDA Receptor Containing GLUN2A as Targets in Screening Drugs for Treating Depression | GRIN2A, GRIN2B, GRIN2C | BACE1 811/4885CTSD 2199/4885DPP4 1602/4885 |
| US-20160176924-A1 | MODIFIED PEPTIDES AS POTENT INHIBITORS OF THE PSD-95/NMDA RECEPTOR INTERACTION | PSD, GRIN1, GRIN3B | BACE1 792/4885CTSD 2493/4885DPP4 1418/4885 |
| US-20110178022-A1 | MODIFIED PEPTIDES AS POTENT INHIBITORS OF THE PSD-95/NMDA RECEPTOR INTERACTION | GRIN1, PSD, GRIN3B | BACE1 834/4885CTSD 2491/4885DPP4 1392/4885 |
| US-11878044-B2 | Combination therapy for ischemia | PSD, DAPK2, FABP7 | BACE1 650/4885CTSD 1531/4885DPP4 653/4885 |
| US-20240301003-A1 | PLASMIN-RESISTANT PEPTIDES FOR IMPROVED THERAPEUTIC INDEX | DAO, DNPEP, DDO | BACE1 270/4885CTSD 601/4885DPP4 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.